Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Philippou

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Blood|March 9, 2019
Heavy chain of FXII: not an innocent bystander!Helen Philippou
Thrombosis and Haemostasis|December 14, 2020
New Rapid and Cost-Effective Tool for Monitoring DOACsHelen Philippou
Blood|January 22, 2015
Unexplained bleeding: another player to look out for!Helen Philippou
Blood|July 15, 2021
FXII inhibition: multipronged benefitsHelen Philippou
Thrombosis Research|November 15, 2013
Thrombin activatable fibrinolysis inhibitor (TAFI): more complex when it meets the clotHelen Philippou
Expert Review of Hematology|August 5, 2023
Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XIHelen Philippou, Evi X Stavrou
Thrombosis and Haemostasis|July 22, 2016
Recommendation for ISTH/SSC Criterion 2015 for autoimmune acquired factor XIII/13 deficiencyAkitada Ichinose, Hans P Kohler, Helen Philippou, et al.
The New England Journal of Medicine|March 26, 2025
Asundexian versus Apixaban in Patients with Atrial FibrillationSam Straw, Klaus K Witte, Helen Philippou
Neuroscience|March 7, 2024
Ischaemic Stroke, Thromboembolism and Clot StructureKatherine Stanton, Helen Philippou, Robert As Ariëns
Journal of Medicinal Chemistry|May 29, 2020
Progress toward a Glycoprotein VI Modulator for the Treatment of ThrombosisHolly Foster, Clare Wilson, Helen Philippou, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Blood|March 9, 2019
Heavy chain of FXII: not an innocent bystander!Helen Philippou
Thrombosis and Haemostasis|December 14, 2020
New Rapid and Cost-Effective Tool for Monitoring DOACsHelen Philippou
Blood|January 22, 2015
Unexplained bleeding: another player to look out for!Helen Philippou
Blood|July 15, 2021
FXII inhibition: multipronged benefitsHelen Philippou
Thrombosis Research|November 15, 2013
Thrombin activatable fibrinolysis inhibitor (TAFI): more complex when it meets the clotHelen Philippou
Expert Review of Hematology|August 5, 2023
Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XIHelen Philippou, Evi X Stavrou
Thrombosis and Haemostasis|July 22, 2016
Recommendation for ISTH/SSC Criterion 2015 for autoimmune acquired factor XIII/13 deficiencyAkitada Ichinose, Hans P Kohler, Helen Philippou, et al.
The New England Journal of Medicine|March 26, 2025
Asundexian versus Apixaban in Patients with Atrial FibrillationSam Straw, Klaus K Witte, Helen Philippou
Neuroscience|March 7, 2024
Ischaemic Stroke, Thromboembolism and Clot StructureKatherine Stanton, Helen Philippou, Robert As Ariëns
Journal of Medicinal Chemistry|May 29, 2020
Progress toward a Glycoprotein VI Modulator for the Treatment of ThrombosisHolly Foster, Clare Wilson, Helen Philippou, et al.
Pageof 6